Substance and claimed effects

Pterostilbene is a methylated stilbene — chemically 3,5-dimethoxy-4'-hydroxystilbene, the dimethyl ether analog of resveratrol — found naturally in blueberries (roughly 100-500 ng per gram of fresh fruit), grapes, and the heartwood of the Indian Kino tree (Pterocarpus marsupium). Sold as a 50-250 mg/day capsule for longevity, metabolic, cognitive, and anti-inflammatory benefit, often as part of NAD+-booster stacks (Elysium Basis pairs 50 mg pterostilbene with 250 mg nicotinamide riboside). Vendor claims span SIRT1/AMPK-mediated longevity signalling, blood-pressure reduction, cognitive support in aging, anti-inflammatory action via NF-κB, glycemic control, and "better resveratrol" lipid handling. This entry covers each — particularly the consequence the prevailing literature most clearly establishes in humans: an LDL increase that complicates the cardiometabolic case (Riche 2014).

Evidence by addressing question

Mechanism

Pterostilbene activates the SIRT1 deacetylase and AMPK kinase, the two longevity-sensor pathways that resveratrol also targets. Downstream consequences include PGC-1α activation, mitochondrial biogenesis, and reduced reactive oxygen species (McCormack & McFadden 2013). Methylation of resveratrol's hydroxyls produces two clinically relevant differences: lipophilicity rises sharply (improved membrane permeability and brain penetration in preclinical models), and the phase-II glucuronidation that destroys most oral resveratrol is partially bypassed (Dutta et al. 2023). In the only head-to-head pharmacokinetic comparison, oral bioavailability in rats was approximately 80% for pterostilbene versus approximately 20% for resveratrol, with plasma exposure of the parent compound an order of magnitude higher (Kapetanovic et al. 2011). Anti-inflammatory effects in cell and animal models trace to NF-κB suppression: pterostilbene reduces phosphorylation of IκBα and IKK-α/β, lowering nuclear p65 translocation and downstream TNF-α, IL-6, and nitric oxide (McCormack & McFadden 2013). A separate mechanistic strand connects to the lipid signal: in HL-1 cardiomyocytes, pterostilbene increased LDL-receptor expression and uptake via PCSK9/SREBP2 modulation — a story consistent with the human LDL data going either direction depending on receptor location and tissue compartment.

Evidence

The only well-powered human efficacy trial is the Riche group's RCT: 80 hypercholesterolemic adults across four arms — placebo, 100 mg/day pterostilbene, 250 mg/day pterostilbene, or 100 mg/day pterostilbene plus 200 mg/day grape extract — split twice daily, for 6-8 weeks. The high-dose arm dropped systolic blood pressure by −7.8 mmHg (P < 0.01) and diastolic by −7.3 mmHg (P < 0.001) — a clinically meaningful reduction in the range of a low-dose antihypertensive. But LDL cholesterol rose by +17.1 mg/dL in the pterostilbene-monotherapy pooled groups (P = 0.001), an effect not seen when grape extract was co-administered. Subjects on a statin at baseline did not show the LDL rise (Riche et al. 2014). The companion safety paper from the same cohort found no signal on liver enzymes, creatinine, or glucose at 250 mg/day and supported the FDA GRAS notifications that followed (Riche et al. 2013).

The second well-controlled trial is Jensen et al.: 32 elderly subjects (55-80) randomized to NRPT (1,000 mg/day nicotinamide riboside + 200 mg/day pterostilbene) or placebo for 6 weeks around an experimentally induced muscle injury. NRPT raised whole-blood NAD+ substantially and reproducibly — and failed every primary endpoint: no improvement in muscle stem cell content, strength recovery, soreness scores, or histological regeneration markers (Jensen et al. 2022). This is the clearest functional test of the NAD+-pterostilbene stack to date and it was negative despite reliable target engagement.

Human cognition evidence is absent. Animal cognition evidence is encouraging: aged rats on pterostilbene outperform controls on working-memory tasks and the SAMP8 accelerated-aging mouse shows cognitive improvement with markers of reduced cellular stress and neuroinflammation (Dutta et al. 2023). Human longevity evidence is absent — the available data are surrogate NAD+ measurements, not hard endpoints. Cancer-prevention evidence is preclinical only.

Protocol

Commercial doses span 50-250 mg/day. The Riche 2014 trial used 100 mg (low) and 250 mg (high) split BID (Riche et al. 2014). Elysium Basis stacks 50 mg pterostilbene with 250 mg nicotinamide riboside once daily. Pterostilbene is lipophilic and absorption is improved with a fatty meal. No human dose-response curve has been published; the 250 mg/day ceiling carries forward from the safety trial (Riche et al. 2013).

Contraindications

No specific drug-interaction or population-level contraindications are well documented. Pregnancy and lactation: untested. The LDL signal warrants caution in anyone with baseline dyslipidemia who is not already on a statin — the statin subgroup in Riche 2014 was protected from the LDL rise, but the rest of the cohort was not (Riche et al. 2014). The grape-extract co-administration attenuated the lipid effect in the trial but no follow-up has confirmed the protection.

Misconceptions

"Pterostilbene is just a better resveratrol because of bioavailability." Higher plasma exposure is not a clinical outcome. The bioavailability advantage was measured in rats (Kapetanovic et al. 2011); the only well-powered human efficacy trial showed mixed signal with an adverse lipid component (Riche et al. 2014). Marketing pages routinely transpose preclinical resveratrol mechanisms (sirtuin activation, mitochondrial biogenesis, cancer prevention) onto pterostilbene as if the human evidence were equivalent. It is not. "NAD+ booster stacks work." NRPT supplementation reliably raises blood NAD+. In the cleanest functional test to date, that NAD+ rise translated to nothing measurable (Jensen et al. 2022).

Practicalities

Available widely as a standalone capsule (typically 50-150 mg) or as part of a longevity stack. Bulk standalone pricing is roughly $15-40/year at 100-250 mg/day; brand-name stacks (Basis, Tru Niagen and analogs) run $300-600/year. Standardised trans-pterostilbene (the bioactive isomer) from reputable manufacturers carries third-party purity testing; the dietary supplement market is otherwise unregulated for content.

Failure modes

The well-documented failure is LDL elevation in subjects not on statin therapy (Riche et al. 2014). The undocumented failure mode is the assumption that "more bioavailable resveratrol" carries the resveratrol claim portfolio into the clinic — a leap the human evidence does not support, and that resveratrol itself has repeatedly failed in human RCTs of aging endpoints.

Stakes

Continuing to take pterostilbene without monitoring trades a known adverse lipid signal for unproven longevity benefit. Continuing to skip it forgoes a plausible cellular-signalling molecule that the human evidence has not yet shown does anything beneficial outside of blood pressure at the highest tested dose. Neither side of this trade is large.

Out of scope

Resveratrol (the parent compound, with its own large but unconvincing human trial portfolio) and nicotinamide riboside / NMN (the NAD+ precursor story, frequently stacked) are adjacent entries.

History

Identified in Pterocarpus marsupium heartwood in 1940 and used in Ayurvedic medicine for diabetes long before isolation. Brought into Western longevity research as part of the resveratrol-analog wave following Sinclair's early 2000s SIRT1 work. Commercialised through ChromaDex's pTeroPure ingredient in the early 2010s and Elysium Basis (launched 2014, advised by NAD+ researcher Leonard Guarente). ChromaDex stopped taking new pterostilbene orders after the Riche 2014 LDL data was published, citing the cholesterol signal.

The credibility range

Optimist case

Pterostilbene replicates the resveratrol mechanism portfolio (SIRT1, AMPK, PGC-1α, NF-κB) with four-fold higher bioavailability, brain penetration, and a clean safety profile up to 250 mg/day across hepatic, renal, and glycemic markers (Riche et al. 2013). Animal data on cognitive aging is consistent across multiple models. The systolic and diastolic blood pressure reductions in Riche 2014 are clinically meaningful and reproducible in mechanism. The LDL increase is reversed when co-administered with grape extract, suggesting a co-formulation path. The Jensen muscle-injury trial chose a hard acute-recovery endpoint that any chronic-use longevity supplement might be expected to miss. For someone optimising on longevity priors, a plausible mechanism plus animal cognition plus measured BP reduction at ~$30/year is a defensible bet.

Skeptic case

One human efficacy trial in 80 subjects is not an evidence base. The only direct human lipid measurement showed pterostilbene raised LDL by 17.1 mg/dL — directionally the opposite of what a cardiometabolic supplement should do (Riche et al. 2014). The Jensen 2022 NRPT trial was a clean test of NAD+-mediated functional benefit in the target demographic and failed every endpoint despite reliable target engagement (Jensen et al. 2022). No human trial has tested cognition; no human trial has tested longevity. The mechanism extrapolation from resveratrol is precisely the preclinical-to-human leap that resveratrol itself has repeatedly failed to clear in controlled trials. Commercial incentives are strong: pterostilbene anchored a multi-million-dollar supplement category before any positive human efficacy trial supported the central claims.

Author's call

Pterostilbene is a plausible molecule with thin and mixed human evidence and a clearly documented adverse signal on LDL cholesterol. The longevity case is preclinical extrapolation; the one cardiovascular signal cuts in two directions (BP down, LDL up); the one rigorous functional trial in the target demographic was negative. This is a "decide" entry, not a "do" entry — and readers with baseline dyslipidemia who are not on a statin should be especially cautious. Evidence score 2; controversy score 3.

Stakeholder and incentive map

• Supplement makers and longevity brands (Elysium Health, NOVOS, ChromaDex/pTeroPure originators) pushed pterostilbene as both a standalone and as a NAD+-stack component for most of the last decade.
• Academic longevity researchers (Guarente and adjacent NAD+ groups) legitimised the category through advisory roles, even as the human efficacy evidence lagged the commercial rollout.
• Skeptics include independent clinical nutritionists and the editorial responses to Riche 2014 that triggered ChromaDex's halt on new pterostilbene orders.
• Regulatory side: GRAS notification accepted at 250 mg/day; no FDA drug approval; sold as a dietary supplement, with the labelling latitude that implies.

Population variability

The only direct human efficacy data is in hypercholesterolemic adults (Riche et al. 2014), so generalisation to healthy populations is uncertain. The LDL effect was absent in the statin subgroup and attenuated by grape-extract co-administration. The NRPT muscle-injury trial enrolled 55-80 year-olds — the explicit "longevity" target demographic — and showed no functional benefit (Jensen et al. 2022). No published data in young healthy adults. No sex-stratified efficacy data. The animal cognition data is exclusively in aged rodents (Dutta et al. 2023).

Knowledge gaps

What hasn't been studied in humans: chronic (more than 8 weeks) supplementation on any endpoint; cognition in any population; cardiovascular hard endpoints; longevity surrogates beyond NAD+. The LDL question needs replication — the Riche finding is mechanistically corroborated in cardiomyocyte work but no second well-powered RCT has measured the same outcome. What would change the call: a positive 6-12 month cognitive RCT in healthy aging adults; a confirmation or refutation of the LDL signal in a non-hypercholesterolemic cohort; any hard-endpoint cardiovascular data; a positive functional readout from NAD+ supplementation in a well-controlled trial.

Brief coverage. The input description named blood lipids, blood sugar, inflammation, cognition, and cellular-aging pathways. All five are touched in the article. The honest weighting: the LDL signal from Riche 2014 is the single most consequential finding in the human evidence base, so lipids carry the most weight (in the dek, the science callout, the warning, and the stakes section). Blood sugar gets one line in the science callout because there was no signal to discuss. Cognition and cellular-aging are scoped as "mechanism is plausible, no human evidence" — not silently dropped, but honestly framed. Inflammation is folded into the mechanism paragraph rather than given its own section, because no human anti-inflammatory trial exists.

Hard scoring calls.

• evidence: 2 — Riche 2014 is a real RCT (n=80) with mixed primary outcomes, Jensen 2022 is well-controlled and negative on every endpoint despite reliable target engagement, and safety is well-established. That fits "sparse or contested literature; mechanism plausible but trials thin or mixed" better than the "small or preliminary studies" of evidence-3.
• controversy: 3 — ChromaDex stopped taking new pterostilbene orders after the Riche LDL finding while Elysium and adjacent longevity brands continued promoting it. Active expert disagreement, not just minor pushback.
• longevity: 1 and health_short_term: 1 — both are marginal scores rather than zeros because the mechanism is genuinely plausible and BP did drop at 250 mg/day. But the LDL signal cuts directly against the cardiovascular case, so a 2 would overstate the human evidence.
• action: decide rather than do or avoid — the evidence is not strong enough either to recommend the supplement or to actively warn off; the LDL question is a real tradeoff a reader should weigh, ideally with a lipid panel before and after. cadence: daily reflects what the reader does if they decide to take it.
• applicability: 2 — niche to the longevity-supplement-considering slice of adults, not a universal health concern.

Dream narrative. Written despite the overall score (≈10) being well below the 40 obligation threshold, because the honest hook is the relief / clarity lever — the version of the reader who saw the evidence in time, stopped paying for it, and freed the mental real estate. A "skip it" entry still earns a brief narrative when relief is the genuine payoff.

Citation library note. The Riche2014 entry's stored title accidentally merges the safety-paper title with the metabolic-parameters paper's subtitle (author error at add_citation time; no update tool was available). The DOI is correct (10.1155/2014/459165 → "Pterostilbene on Metabolic Parameters: A Randomized, Double-Blind, and Placebo-Controlled Trial"), so all article citations resolve to the right paper. Flagging for a future librarian pass.

Future-link candidates. Adjacent entries that don't exist yet but this one should cross-link to once they do: resveratrol, nicotinamide riboside, NMN, and a general NAD+ booster category entry. A statin decision entry would be relevant to the LDL warning, since the trial's statin-using subgroup was protected.

Separate-entry candidates. The NRPT / NAD+-precursor story is its own entry's worth of material — Jensen 2022 is cited here as the cleanest functional test of pterostilbene + NR together, but the broader NAD+ supplementation question belongs in an NR / NMN entry.